Park­er In­sti­tute sci­en­tists her­ald a cell ther­a­py break­through in the lab, us­ing next-gen CRISPR tech to en­gi­neer T cells

The two pi­o­neer­ing CAR-T ther­a­pies on the mar­ket — Kym­ri­ah and Yescar­ta — re­ly on vi­ral vec­tors to com­plete the en­gi­neer­ing work need­ed to make a can­cer pa­tient’s T cells in­to a ther­a­py. But a group of Park­er In­sti­tute for Can­cer Im­munother­a­py-backed sci­en­tists at UCSF and UCLA say they have per­fect­ed a new ap­proach us­ing CRISPR gene edit­ing tech that they be­lieve will trans­form the field — open­ing the door to a range of cell ther­a­pies that can be built and man­u­fac­tured far more eas­i­ly than the first-gen crowd.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.